GlassScriptPhysician profile
Alfred Raul Leal
NPI 1629071428
$546.32
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $546.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $87.72 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $41.90 | 2019 | |
| Incyte Corporation | $28.34 | 2019 | |
| Tersera Therapeutics LLC | $27.16 | 2019 | |
| Pfizer INC. | $26.77 | 2019 | |
| Amgen INC. | $26.30 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $23.93 | 2019 | |
| Janssen Biotech, INC. | $21.20 | 2019 | |
| Genzyme Corporation | $18.67 | 2019 | |
| Heron Therapeutics, INC. | $18.15 | 2019 | |
| Genentech USA, INC. | $18.14 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $17.64 | 2019 | |
| Array Biopharma INC | $17.48 | 2019 | |
| Eisai INC. | $17.40 | 2019 | |
| Abbvie INC. | $16.41 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $14.42 | 2019 | |
| Gilead Sciences, INC. | $14.27 | 2019 | |
| Clovis Oncology, INC. | $13.49 | 2019 | |
| Celgene Corporation | $13.42 | 2019 | |
| Merck Sharp & Dohme LLC | $13.04 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $12.38 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.12 | 2019 | |
| Seagen INC. | $11.98 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $11.91 | 2019 | |
| Spectrum Pharmaceuticals INC. | $11.47 | 2019 | |
| Emd Serono, INC. | $10.61 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alfred Leal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.